11th May 2018 14:41
11 May 2018
Diurnal Group plc
("Diurnal" or the "Company")
Director Declaration
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, makes the following announcement pursuant to Schedule 2, paragraph (g) and AIM Rule 17 of the AIM Rules for Companies. The Company has been informed by Richard Bungay, Chief Financial Officer of the Company, of the following changes to his director details in respect of a directorship:
Mr Bungay was appointed a director of Glide Pharmaceutical Technologies Limited ("Glide") on 1 July 2014. On 31 August 2017, Lindsey Cooper and David Ronald Taylor of RSM Restructuring Advisory LLP were appointed as joint administrators of Glide Pharmaceutical Technologies Limited. A notice of progress report to 7 March 2018 and filed on 15 March 2018 indicated all unsecured creditor balances had been settled. Due to an oversight, this information was not reported to the Company at the time.
For further information, please visit www.diurnal.co.uk or contact: | |
Diurnal Group plc | +44 (0)20 3727 1000 |
Martin Whitaker, Chief Executive Officer | |
Richard Bungay, Chief Financial Officer | |
Numis Securities Ltd (Nominated Adviser) | +44 (0)20 7260 1000 |
Nominated Adviser: Michael Meade, Paul Gillam, Freddie Barnfield | |
Corporate Broking: James Black | |
Panmure Gordon (UK) Limited (Joint Broker) | +44 (0) 20 7886 2500 |
Corporate Finance: Freddy Crossley, Emma Earl | |
Corporate Broking: James Stearns | |
FTI Consulting (Investor Relations) | +44 (0)20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell | |
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
Related Shares:
DNL.L